Erasca Shares Fall 5% on Trial Data

Erasca shares fell about 5% in after‑hours trading after releasing Phase 1 data for its pan‑RAS drug ERAS‑0015.
In KRAS G12X non‑small cell lung cancer, ERAS‑0015 achieved a 62% unconfirmed overall response rate at 16‑32 mg daily.
In KRAS G12X pancreatic cancer, the drug showed a 40% unconfirmed overall response rate at the same dose range.
The trial reported good tolerability, no dose‑limiting toxicities, and set 24 mg and 32 mg daily as expansion doses, with further data expected H1 2027.